XML 44 R34.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2025
Segment Information [Abstract]  
Segment Information
The following table sets forth information on segment profit or loss, including significant segment expenses (in thousands):
 
 Three Months Ended Nine Months Ended
 September 30, September 30,
 2025 2024 2025 2024
Revenue$156,719  $133,814  $740,381  $478,562 
        
Less:       
Cost of sales 2,193   912   7,097   6,815 
Drug discovery 28,412   25,790   85,656   80,652 
Drug development 120,828   132,201   351,463   392,151 
Medical affairs 8,874   5,511   22,342   17,279 
Manufacturing and development chemistry 15,790   14,087   51,616   39,723 
R&D support 23,092   20,052   64,252   59,065 
Selling, general and administrative 86,565   51,933   234,626   153,083 
Other segment items (1) (429)   23,808   75,322   79,342 
Consolidated net loss$(128,606)  $(140,480)  $(151,993)  $(349,548) 
 
(1)  Other segment items include stock-based compensation expense, investment income, interest expense, gain or loss on investments, other income or expense and income tax expense or benefit.